Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Regeneron Pharmaceuticals IncTrade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Vanguard S&P 500 ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while Vanguard S&P 500 ETF trades at $701.71. The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals.

	REGN	VOO
Market Cap	$83.15B	—
Sector	Health	Broad Market / Factor
52-Week High	$852.03	$714.90
52-Week Low	$555.51	$580.93
Enterprise Value	$77.86B	—
Dividend Yield	0.47%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.

The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.

Vanguard S&P 500 ETF

VOO trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. Support is firm near $701, while resistance sits at $707. The ETF remains a core S&P 500 holding, with recent news highlighting its tax efficiency versus gold ETFs and strong inflows amid record ETF launches in 2026.

Long-term outlook remains positive given historical S&P 500 performance, though risks include elevated market valuations and Fed policy uncertainty. The ETF offers broad market exposure, but investors face potential volatility from macroeconomic factors and high concentration in top AI-driven companies.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

REGN

Michael Burry bets against AI hype, buying call options on beaten-down stocks like UnitedHealth, Regeneron, and Lululemon.24/7 Wall Street · 2 days agoBullish Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish View details →

VOO

Gold ETF gains taxed at 28%, nearly double S&P 500 ETF's 15% rate, costing investors thousands more.24/7 Wall Street · 16 hours agoBearish Four ETFs combine dividend income and total return to balance retirement income and growth risks.24/7 Wall Street · 1 day agoBullish S&P 500 moves with Fed rate hike odds; key 7620 level could signal buying opportunity after September CPI.Seeking Alpha · 2 days agoNeutral View details →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.